[ad_1]
The December 3 letter reports that study participants retained high levels of neutralizing antibodies for 119 days after the first vaccination (90 days after the second vaccination). The results were consistent in all age cohorts (18-55, 56-70 and older than 71 years) and, despite an expected slight decrease in neutralizing and binding antibody titers, mRNA-1273 has the potential to provide long-lasting humoral immunity, according to the researchers.
Additionally, no serious adverse events were seen in the trial, pre-specified rules to stop the trial were not followed, and no new adverse events that were considered vaccine-related occurred after day 57, according to the researchers.
Moderna reaffirmed that it expects to have approximately 20 million doses available in the US by the end of the year and between 100 million and 125 million doses available globally in the first quarter of 2021. Of those 2021 doses, 85-100 million will be available in the US and between 15 and 25 million will be available outside the US.
In other Moderna news, the firm announced an expanded supply agreement with Israel’s Ministry of Health for an additional 4 million doses of mRNA-1273. The Israeli government has now secured 6 million doses of the vaccine and will support the ministry’s ongoing efforts to ensure early access to a COVID-19 vaccine. Moderna has already started the ongoing regulatory review process with the Israeli Health Ministry, the firm said.
Copyright © 2020 scienceboard.net
